ArticleBiophysical reviews2017
New perspectives in nanotherapeutics for chronic respiratory diseases.
Article in Biophysical reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of the treatment modalities available for children afflicted from cystic fibrosis.BMC pediatrics · 2025Pooled it
- Development of Mannitol-Based Microparticles for Dry Powder Inhalers: Enhancing Pulmonary Delivery of NSAIDs.Pharmaceuticals (Basel, Switzerland) · 2025Article
- MicroRNAs as promising drug delivery target to ameliorate chronic obstructive pulmonary disease using nano-carriers: a comprehensive review.Molecular and cellular biochemistry · 2025Review
- Spray-Dried Nanolipid Powders for Pulmonary Drug Delivery: A Comprehensive Mini Review.Pharmaceutics · 2024Review
- On the path to predicting immune responses in the lung: Modeling the pulmonary innate immune system at the air-liquid interface (ALI).European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2023Review
- Novel biocatalysts based on enzymes in complexes with nano- and micromaterials.Biophysical reviews · 2023Review
- Aerosol pulmonary immune engineering.Advanced drug delivery reviews · 2023Review
- Arctiin-encapsulated DSPE-PEG bubble-like nanoparticles inhibit alveolar epithelial type 2 cell senescence to alleviate pulmonary fibrosisFrontiers in pharmacology · 2023Article
- Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases.Journal of drug delivery science and technology · 2022Review
- Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases.Future medicinal chemistry · 2022Review
- Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions.Biomolecules · 2022Review
- Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis.Frontiers in pharmacology · 2022Article
- Titanium Dioxide Nanoparticles Exacerbate Allergic Airway Inflammation via TXNIP Upregulation in a Mouse Model of Asthma.International journal of molecular sciences · 2021Article
- Recent applications and strategies in nanotechnology for lung diseases.Nano research · 2021Review
- Routine, ensemble characterisation of electrophoretic mobility in high and saturated ionic dispersions.Scientific reports · 2020Article
- Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases.International journal of nanomedicine · 2020Review
- Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- An Inflamed Human Alveolar Model for Testing the Efficiency of Anti-inflammatory DrugsFrontiers in bioengineering and biotechnology · 2020Article
- Nanotechnology bring a new hope for asthmatics.Annals of translational medicine · 2019Article
- How will nanotechnology lead to better control of asthma?Annals of translational medicine · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the World Health Organization (WHO), hundreds of millions of people of all ages and in all countries suffer from chronic respiratory diseases, with particular negative consequences such as poor health-related quality of life, impaired work productivity, and limitations in the activities of daily living. Chronic obstructive pulmonary disease, asthma, occupational lung diseases (such as silicosis), cystic fibrosis, and pulmonary arterial hypertension are the most common of these diseases, and none of them are curable with current therapies. The advent of nanotechnology holds great therapeutic promise for respiratory conditions, because non-viral vectors are able to overcome the mucus and lung remodeling barriers, increasing pharmacologic and therapeutic potency. It has been demonstrated that the extent of pulmonary nanoparticle uptake depends not only on the physical and chemical features of nanoparticles themselves, but also on the health status of the organism; thus, the huge diversity in nanotechnology could revolutionize medicine, but safety assessment is a challenging task. Within this context, the present review discusses some of the major new perspectives in nanotherapeutics for lung disease and highlights some of the most recent studies in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.